drugset
drugset / Trial / NCT01679951

A Dose Range Finding Study of JNJ-38518168 in Patients With Active Rheumatoid Arthritis in Spite of Treatment With Methotrexate

NCT01679951 ↗

Phase 2 Terminated 272 enrolled Janssen Research & Development, LLC
RandomizedParallel-groupDouble-blindTreatment

Summary

The purpose of this dose range finding study is to assess the effectiveness, safety and tolerability of JNJ-38518168 at doses of 3, 10, and 30 mg/d compared with placebo in patients with active rheumatoid arthritis (RA) despite concomitant methotrexate (MTX) therapy.

Timeline

Start
2012-10-31
Primary completion
2014-04-17
Completion
2014-07-03

Drugs

EvaluationDrugModalityDoseRoute
Subject TOREFORANT Small molecule 3 mg Oral
Subject TOREFORANT Small molecule 10 mg Oral
Subject TOREFORANT Small molecule 30 mg Oral
Background Methotrexate Small molecule — —

Indications

rheumatoid arthritis